Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine.
We evaluated liver P450 enzyme system induction and serum lipid levels in a prospective follow-up study in 12 male patients with epilepsy after replacing carbamazepine (CBZ) medication with oxcarbazepine (OCBZ). Antipyrine(t1/2) increased and antipyrine(CL) decreased 2 months after the medication was changed, reflecting normalization of liver P450 enzyme system function. Furthermore, serum total cholesterol levels decreased, but serum concentrations of high-density lipoprotein (HDL)-cholesterol and triglycerides (TG) were unchanged. OCBZ may be the preferable antiepileptic drug (AED) with regard to the effects of the medication on lipid metabolism.
Isojärvi
J I
JI
Department of Neurology, University of Oulu, Finland.
Pakarinen
A J
AJ
Rautio
A
A
Pelkonen
O
O
Myllylä
V V
VV
D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D000983:Antipyrine / Q000097:blood; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004790:Enzyme Induction / Q000187:drug effects*; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D000078330:Oxcarbazepine; D014280:Triglycerides / Q000097:blood
D000927:Anticonvulsants; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D002220:Carbamazepine; D003577:Cytochrome P-450 Enzyme System; D000983:Antipyrine; D000078330:Oxcarbazepine